238427-63-9

Basic information

• Product Name: Carbamic acid, [[4-[(methylsulfonyl)amino]phenyl]methyl]-, 1,1-dimethylethyl ester
• CAS NO: 238427-63-9
• Molecular Formula: C13H20N2O4S
• Molecular Weight: 300.379
• Mol File: 238427-63-9.mol
• Article Data: 8

Chemical Properties

• CAS DataBase Reference: Carbamic acid, [[4-[(methylsulfonyl)amino]phenyl]methyl]-, 1,1-dimethylethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Carbamic acid, [[4-[(methylsulfonyl)amino]phenyl]methyl]-, 1,1-dimethylethyl ester(238427-63-9)
• EPA Substance Registry System: Carbamic acid, [[4-[(methylsulfonyl)amino]phenyl]methyl]-, 1,1-dimethylethyl ester(238427-63-9)

Safety Data

• Hazardous Substances Data: 238427-63-9(Hazardous Substances Data)

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 94838-58-1 tert-butyl 4-nitrobenzylcarbamate 
• 18600-42-5 4-nitrobenzylamine hydrochloride 
• 4403-71-8 (4-aminomethyl)aniline 
• 124-63-0 methanesulfonyl chloride 
• 94838-55-8 tert-butyl (4-aminobenzyl)carbamate 

Downstream Products

• 128263-66-1 N-<4-(aminomethyl)phenyl>methanesulfonamide hydrochloride 
• 401573-42-0 N-(4-isothiocyanatomethylphenyl)methanesulfonamide 
• 676463-29-9 [4-(methanesulfonyl-methyl-amino)-benzyl]-carbamic acid tert-butyl ester 
• 129872-50-0 N-<4-(aminomethyl)phenyl>methanesulfonamide 

Relevant articles and documents

ADENINE DERIVATIVES AS PROTEIN KINASE INHIBITORS

The present invention relates to a compound suitable for use as a kinase inhibitor according to general formula (I) [compound (C), herein after], or the N- oxide, pharmaceutically acceptable salt, pharmaceutically acceptable solvate, or stereoisomer thereof, formula (I) wherein A, R1, R2, R3, R3', R4, R4', X, Y, Z, T are as defined in the claims. The invention further relates to an in vitro method of inhibiting protein kinase activity which comprises contacting a protein kinase with a compound of formula (I), or the N-oxide, pharmaceutically acceptable salt, pharmaceutically acceptable solvate, or stereoisomer thereof. The invention further relates to the compounds of formula (I) per se, as well as to their use as a medicament, and for use or in a method of treatment of a disease mediated by a protein kinase selected from cancer, inflammatory disorders, cardiovascular diseases, viral induced diseases, circulatory diseases, fibro-proliferative diseases and pain sensitization disorders.

N-4-Substituted-benzyl-N′-tert-butylbenzyl thioureas as vanilloid receptor ligands: Investigation on the role of methanesulfonamido group in antagonistic activity

A series of N-4-substituted-benzyl-N′-tert-butylbenzyl thioureas were prepared for the study of their agonistic/antagonistic activities to the vanilloid receptor in rat DRG neurons. Their structure-activity relationship reveals that not only the two oxyge

Novel non-vanilloid VR1 antagonist of high analgesic effects and its structural requirement for VR1 antagonistic effects

A novel non-vanilloid VR1 antagonist consisting of a new vanilloid equivalent exhibits excellent analgesic effects as well as highly potent antagonistic activities in both capsaicin single channel and calcium uptake assays. In addition, the structural requirement for the vanilloid equivalent of the potent VR1 antagonist has also been elucidated.